Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME)
ABSTRACT Introduction Chlorophyllin (CHL) effectively decreases the side effects of radiotherapy (RT) by scavenging radiation‐induced free radicals and reactive oxygen species in preclinical trials. This study aims to assess the efficacy of oral CHL for the treatment of brain radionecrosis in patien...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70657 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850052760764940288 |
|---|---|
| author | Archya Dasgupta Saranga Sawant Abhishek Chatterjee Vikram Gota Arpita Sahu Amitkumar Choudhari Kajari Bhattacharya Ameya Puranik Indraja Dev Aliasgar Moiyadi Prakash Shetty Vikas Singh Nandini Menon Sridhar Epari Ayushi Sahay Aekta Shah Nazia Bano Farnaz Shaikh Aabha Jirage Tejpal Gupta |
| author_facet | Archya Dasgupta Saranga Sawant Abhishek Chatterjee Vikram Gota Arpita Sahu Amitkumar Choudhari Kajari Bhattacharya Ameya Puranik Indraja Dev Aliasgar Moiyadi Prakash Shetty Vikas Singh Nandini Menon Sridhar Epari Ayushi Sahay Aekta Shah Nazia Bano Farnaz Shaikh Aabha Jirage Tejpal Gupta |
| author_sort | Archya Dasgupta |
| collection | DOAJ |
| description | ABSTRACT Introduction Chlorophyllin (CHL) effectively decreases the side effects of radiotherapy (RT) by scavenging radiation‐induced free radicals and reactive oxygen species in preclinical trials. This study aims to assess the efficacy of oral CHL for the treatment of brain radionecrosis in patients with diffuse glioma. Methods This is a phase 2 trial prospective, interventional study. Adults (> 18 years) with a histological diagnosis of diffuse glioma developing radionecrosis will be eligible for the study. Radionecrosis will be identified using standard imaging protocols with magnetic resonance imaging (MRI) with or without positron emission tomography (PET). Patients will be accrued in two strata: symptomatic (stratum A) and asymptomatic (stratum B). Chlorophyllin will be prescribed to all patients using a morning oral dose of 750 mg before breakfast for 3 months. In addition, participants in stratum A will be given a tapering dose of dexamethasone for 1 month, while stratum B will not be receiving any steroids. Imaging with an MRI brain protocol and PET scan will be planned at 1 month and MRI at 3 months after starting CHL. The primary endpoint is the clinical‐radiological response at 1 month. Secondary endpoints include response at 3 months, biological responses, survival analysis, and quality‐of‐life scores. The total sample size is 118 (60 and 58 in stratum A and B, respectively), with one interim analysis planned. Discussion Radionecrosis leads to significant morbidity and is usually treated with corticosteroids, which can lead to several side effects from both acute and long‐term use. Refractory radionecrosis requires treatment with bevacizumab or surgical resection. Chlorophyllin is a cheap, safe, and readily available phytopharmaceutical drug, which is being investigated in the phase 2 study and, if proven effective, can be considered an alternative for treating radionecrosis. Trial Registration: Clinical Trial Registry India (CTRI): CTRI/2023/08/056166; ClinicalTrials.gov: NCT06016452 |
| format | Article |
| id | doaj-art-bd470ca0bf80467c9909ee86a03b1438 |
| institution | DOAJ |
| issn | 2045-7634 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-bd470ca0bf80467c9909ee86a03b14382025-08-20T02:52:44ZengWileyCancer Medicine2045-76342025-03-01145n/an/a10.1002/cam4.70657Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME)Archya Dasgupta0Saranga Sawant1Abhishek Chatterjee2Vikram Gota3Arpita Sahu4Amitkumar Choudhari5Kajari Bhattacharya6Ameya Puranik7Indraja Dev8Aliasgar Moiyadi9Prakash Shetty10Vikas Singh11Nandini Menon12Sridhar Epari13Ayushi Sahay14Aekta Shah15Nazia Bano16Farnaz Shaikh17Aabha Jirage18Tejpal Gupta19Department of Radiation Oncology Tata Memorial Centre Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaDepartment of Radiation Oncology Tata Memorial Centre Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaHomi Bhabha National Institute (HBNI) Mumbai IndiaDepartment of Radiation Oncology Tata Memorial Centre Mumbai IndiaDepartment of Radiation Oncology Tata Memorial Centre Mumbai IndiaDepartment of Radiation Oncology Tata Memorial Centre Mumbai IndiaDepartment of Radiation Oncology Tata Memorial Centre Mumbai IndiaABSTRACT Introduction Chlorophyllin (CHL) effectively decreases the side effects of radiotherapy (RT) by scavenging radiation‐induced free radicals and reactive oxygen species in preclinical trials. This study aims to assess the efficacy of oral CHL for the treatment of brain radionecrosis in patients with diffuse glioma. Methods This is a phase 2 trial prospective, interventional study. Adults (> 18 years) with a histological diagnosis of diffuse glioma developing radionecrosis will be eligible for the study. Radionecrosis will be identified using standard imaging protocols with magnetic resonance imaging (MRI) with or without positron emission tomography (PET). Patients will be accrued in two strata: symptomatic (stratum A) and asymptomatic (stratum B). Chlorophyllin will be prescribed to all patients using a morning oral dose of 750 mg before breakfast for 3 months. In addition, participants in stratum A will be given a tapering dose of dexamethasone for 1 month, while stratum B will not be receiving any steroids. Imaging with an MRI brain protocol and PET scan will be planned at 1 month and MRI at 3 months after starting CHL. The primary endpoint is the clinical‐radiological response at 1 month. Secondary endpoints include response at 3 months, biological responses, survival analysis, and quality‐of‐life scores. The total sample size is 118 (60 and 58 in stratum A and B, respectively), with one interim analysis planned. Discussion Radionecrosis leads to significant morbidity and is usually treated with corticosteroids, which can lead to several side effects from both acute and long‐term use. Refractory radionecrosis requires treatment with bevacizumab or surgical resection. Chlorophyllin is a cheap, safe, and readily available phytopharmaceutical drug, which is being investigated in the phase 2 study and, if proven effective, can be considered an alternative for treating radionecrosis. Trial Registration: Clinical Trial Registry India (CTRI): CTRI/2023/08/056166; ClinicalTrials.gov: NCT06016452https://doi.org/10.1002/cam4.70657chlorophyllindiffuse gliomaglioblastomahigh‐grade gliomaradionecrosis |
| spellingShingle | Archya Dasgupta Saranga Sawant Abhishek Chatterjee Vikram Gota Arpita Sahu Amitkumar Choudhari Kajari Bhattacharya Ameya Puranik Indraja Dev Aliasgar Moiyadi Prakash Shetty Vikas Singh Nandini Menon Sridhar Epari Ayushi Sahay Aekta Shah Nazia Bano Farnaz Shaikh Aabha Jirage Tejpal Gupta Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME) Cancer Medicine chlorophyllin diffuse glioma glioblastoma high‐grade glioma radionecrosis |
| title | Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME) |
| title_full | Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME) |
| title_fullStr | Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME) |
| title_full_unstemmed | Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME) |
| title_short | Study Protocol of a Prospective Phase 2 Study of Chlorophyllin for the Management of Brain Radionecrosis in Patients With Diffuse Glioma (CHROME) |
| title_sort | study protocol of a prospective phase 2 study of chlorophyllin for the management of brain radionecrosis in patients with diffuse glioma chrome |
| topic | chlorophyllin diffuse glioma glioblastoma high‐grade glioma radionecrosis |
| url | https://doi.org/10.1002/cam4.70657 |
| work_keys_str_mv | AT archyadasgupta studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT sarangasawant studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT abhishekchatterjee studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT vikramgota studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT arpitasahu studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT amitkumarchoudhari studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT kajaribhattacharya studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT ameyapuranik studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT indrajadev studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT aliasgarmoiyadi studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT prakashshetty studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT vikassingh studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT nandinimenon studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT sridharepari studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT ayushisahay studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT aektashah studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT naziabano studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT farnazshaikh studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT aabhajirage studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome AT tejpalgupta studyprotocolofaprospectivephase2studyofchlorophyllinforthemanagementofbrainradionecrosisinpatientswithdiffusegliomachrome |